Clinical Trial VICCBRE1320

Title

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer

Principal Investigator(s)

Vandana Abramson

Details

  • Protocol No. VICCBRE1320
  • Open Date: 08/16/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: The primary objectives of the study are as follows: - To evaluate the safety and tolerability of GDC-0032 administered in combination with docetaxel or paclitaxel - To identify DLTs and estimate the MTD of GDC-0032 in combination with docetaxel or paclitaxel - To identify a recommended dose for future studies for GDC-0032 in combination with docetaxel or paclitaxel
  • Disease Sites: Breast
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Docetaxel; Docetaxel (Taxotere); GDC-0032; Paclitaxel
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01862081
  • Secondary Protocol No: GO27802

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.